We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Digital Scanner Optimized for Visible and Fluorescence Microscopy Applications

By LabMedica International staff writers
Posted on 05 May 2015
A new microscope scanner accessory designed to simplify digital pathology studies was introduced at a recent cancer research conference.

Leica Biosystems (Nussloch, Germany) introduced the Aperio VERSA, a combination digital pathology research scanner for brightfield, fluorescence, and FISH (fluorescence in situ hybridization) imaging, at the April 2015 American Association for Cancer Research annual meeting in Philadelphia (PA, USA). More...


The manufacturer described the Aperio VERSA, which is based on the Leica DM600 B microscope, as combining an unsurpassed optical path with precision stage registration, ensuring accurate, high resolution images for the most sophisticated multiplexing studies. Automatic switching between dedicated brightfield and fluorescent cameras ensures consistent, crisp images. The wide range of objective lenses from 1.25x to 63x, with motorized nose piece for automatic changing, enables users to readily scan slides at their ideal resolution. Furthermore, the automated oiler and oil-immersion lenses for 40x and 63x facilitates capture of the high resolution scans in batch and unattended modes.

Once scanned, the Aperio VERSA images are integrated into a comprehensive range of image analysis solutions. The system can be optimized for local, workstation-based, single user analysis, or enterprise-level, multi-user quantification. With a broad portfolio for the detection and quantification of cellular, subcellular and molecular markers in both brightfield and fluorescence, algorithms are easily tuned, so they can be tailored for specific research requirements.

“The Aperio VERSA is a breakthrough for researchers searching for an affordable solution for their diverse imaging needs,” said Puneet Sarin, vice president and general manager of Leica Biosystems’ pathology imaging business. “This combined introduction of solutions, from advanced staining, to imaging and computerized image analysis, demonstrates our commitment to provide cutting-edge technology to drive new breakthroughs in biomarker discovery. We see the Aperio VERSA and research software as valuable tools for core laboratories, bringing increased efficiency and quality to research.”

Related Links:
Leica Biosystems



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.